Vapotherm Stock (NYSE:VAPO)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$2.18

52W Range

$0.70 - $3.44

50D Avg

$2.15

200D Avg

$1.44

Market Cap

$13.55M

Avg Vol (3M)

$20.28K

Beta

-1.10

Div Yield

-

VAPO Company Profile


Vapotherm, Inc., a medical technology company, focuses on the development and commercialization of proprietary high velocity therapy products used to treat patients of various ages suffering from respiratory distress in the United States and internationally. The company offers precision flow systems, such as Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox that deliver heated, humidified, and oxygenated air at a high velocity to patients through a small-bore nasal interface. It also provides companion products, including Vapotherm Transfer Unit, which allows patients to be transferred between care areas within the hospital or ambulate while on therapy; Q50 compressor, which provides compressed air necessary to run the precision flow systems; aerosol aeroneb adaptor to facilitate delivery of ultrasonic aerosolized medication; aerosol disposable patient circuit that is designed to streamline the provision of continuous and intermittent delivery of aerosol medication; and tracheostomy adaptors. In addition, Vapotherm, Inc. offers ProSoft cannula to provide gentle contact with the skin; and disposable products comprising single-use disposables and nasal interfaces, as well as Oxygen Assist Modules, which helps clinicians maintain oxygen levels within a target range. The company sells its products to hospitals. Vapotherm, Inc. was founded in 1993 and is headquartered in Exeter, New Hampshire.

Show More

Industry

Medical - Devices

Sector

Healthcare

Exchange

NYSE

ADR

-

Country

US

Employees

182

IPO Date

Nov 14, 2018

Website

VAPO Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 23
Service, Other$5.80M
Product Revenue$60.50M

Fiscal year ends in Dec 23 | Currency in USD

VAPO Financial Summary


Dec 23Dec 22Dec 21
Revenue$68.67M$66.80M$113.29M
Operating Income$-39.08M$-77.45M$-56.74M
Net Income$-58.19M$-113.26M$-59.80M
EBITDA$-39.08M$-72.13M$-50.98M
Basic EPS$-0.01$-33.89$-18.44
Diluted EPS$-0.01$-33.89$-18.44

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q3 23Nov 08, 23 | 11:02 PM
Q2 23Aug 08, 23 | 11:04 PM
Q1 23May 06, 23 | 12:08 AM

Peer Comparison


TickerCompany
RPIDRapid Micro Biosystems, Inc.
INVOINVO Bioscience, Inc.
SGHTSight Sciences, Inc.
SSKNSTRATA Skin Sciences, Inc.
NXLNexalin Technology, Inc.
TIVCTivic Health Systems, Inc.
NPCENeuroPace, Inc.
BBLGBone Biologics Corporation
BJDXBluejay Diagnostics, Inc.
HSCSHeart Test Laboratories, Inc.
VVOSVivos Therapeutics, Inc.